Table 3.

Multivariate regression for RFS and OS

VariablenRFSOS
HR95% CIPHR95% CIP
Observation 94 Ref      
AZA maintenance 87 0.73 0.49-1.10 .14 0.84 0.55-1.29 .43 
AML 134 Ref   Ref   
MDS 47 0.38 0.22-0.67 <.001 0.39 0.22-0.71 .002 
Cytogenetic risk groups        
 Good 23 Ref.   Ref   
 Intermediate 75 1.97 0.84-4.66 .12 1.5 0.63-3.57 .36 
 Poor 83 2.43 1.06-5.61 .04 2.13 0.92-4.9 .08 
Active disease 115 Ref   Ref   
Complete remission* 66 0.48 0.3-0.75 .001 0.53 0.33-0.84 .007 
First allo-SCT 166 Ref   Ref.   
Second allo-SCT 15 0.93 0.45-1.90 .83 1.08 0.52-2.24 .84 
Myeloablative conditioning 149 Ref   Ref   
Reduced intensity conditioning 32 1.0 0.58-1.75 .99 1.0 0.56-1.76 .99 
Hematopoietic stem cell source        
 PBSC 115 Ref   Ref   
 Cord blood unit 3.72 0.95-14.62 .06 7.59 1.81-31.8 .006 
 Bone marrow 63 1.53 0.95-2.48 .08 1.26 0.76-2.09 .37 
HCT-CI <4 124 Ref   Ref   
HCT-CI >3 57 1.37 0.9-2.09 .14 1.44 0.93-2.24 .10 
VariablenRFSOS
HR95% CIPHR95% CIP
Observation 94 Ref      
AZA maintenance 87 0.73 0.49-1.10 .14 0.84 0.55-1.29 .43 
AML 134 Ref   Ref   
MDS 47 0.38 0.22-0.67 <.001 0.39 0.22-0.71 .002 
Cytogenetic risk groups        
 Good 23 Ref.   Ref   
 Intermediate 75 1.97 0.84-4.66 .12 1.5 0.63-3.57 .36 
 Poor 83 2.43 1.06-5.61 .04 2.13 0.92-4.9 .08 
Active disease 115 Ref   Ref   
Complete remission* 66 0.48 0.3-0.75 .001 0.53 0.33-0.84 .007 
First allo-SCT 166 Ref   Ref.   
Second allo-SCT 15 0.93 0.45-1.90 .83 1.08 0.52-2.24 .84 
Myeloablative conditioning 149 Ref   Ref   
Reduced intensity conditioning 32 1.0 0.58-1.75 .99 1.0 0.56-1.76 .99 
Hematopoietic stem cell source        
 PBSC 115 Ref   Ref   
 Cord blood unit 3.72 0.95-14.62 .06 7.59 1.81-31.8 .006 
 Bone marrow 63 1.53 0.95-2.48 .08 1.26 0.76-2.09 .37 
HCT-CI <4 124 Ref   Ref   
HCT-CI >3 57 1.37 0.9-2.09 .14 1.44 0.93-2.24 .10 
*

Only patients in CR with count recovery were included in this group.

Close Modal

or Create an Account

Close Modal
Close Modal